SCHEMBL3206863

SCHEMBL3206863

COCCOc1ccc(/C=C/C(=O)O)c(OCc2ccc(Cl)cc2Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 1/20 0.47
PTGFR P43088 1/20 0.47
PTGER3 P43115 1/20 0.47
PTGER2 P43116 1/20 0.47
PTGIR P43119 1/20 0.47
PTGDR Q13258 1/20 0.47
NR4A2 P43354 2/20 0.46
PPARG P37231 2/20 0.46
SLC26A4 O43511 1/20 0.45
POLB P06746 1/20 0.45
HDAC8 Q9BY41 7/20 0.44
MAPT P10636 3/20 0.44
NR4A1 P22736 1/20 0.44
NR4A3 Q92570 1/20 0.44
PLA2G1B P04054 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
FABP3 P05413 1/20 0.43
FABP4 P15090 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3206882 1.00 TBXA2R (0.47) TBXA2RPTGFRPTGER3PTGER2PTGIR
SCHEMBL3194736 0.82 PTGER3 (0.45) TBXA2RPTGFRPTGER3PTGER2PTGIR
SCHEMBL3194755 0.82 PTGER3 (0.45) TBXA2RPTGFRPTGER3PTGER2PTGIR
SCHEMBL3217276 0.81 PPARG (0.73) PPARG
SCHEMBL3217266 0.81 PPARG (0.73) PPARG
SCHEMBL3208404 0.81 HDAC8 (0.64) PTGER3PTGER2PTGDRHDAC8MAPT
SCHEMBL3208391 0.81 HDAC8 (0.64) PTGER3PTGER2PTGDRHDAC8MAPT
SCHEMBL3202459 0.80 PPARG (0.67) PPARGHDAC8MAPTPLA2G1BATG4B
SCHEMBL3202491 0.80 PPARG (0.67) PPARGHDAC8MAPTPLA2G1BATG4B
SCHEMBL3215957 0.77 PPARG (0.50) PPARGPOLBHDAC8MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 TBXA2R 2343/4885PTGFR 933/4885PTGER3 2459/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 TBXA2R 1886/4885PTGFR 611/4885PTGER3 2522/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 TBXA2R 2343/4885PTGFR 933/4885PTGER3 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.